Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer.
Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer.
复制标题
EBAG9/RCAS1的表达与人类上皮卵巢癌的晚期疾病有关。
DOI：
10.1038/sj.bjc.6601832
复制
发表时间：
2004-06-01
影响因子：
8.8
通讯作者：
Yaegashi, N
中科院分区：
文献类型：
--
作者：
Akahira, J;Aoki, M;Suzuki, T;Moriya, T;Niikura, H;Ito, K;Inoue, S;Okamura, K;Sasano, H;Yaegashi, N
雌激素受体结合片段相关基因 9 (EBAG9) 是在 MCF-7 人乳腺癌细胞系中鉴定的雌激素反应基因。它与 RCAS 1 相同，RCAS 1 是一种可能参与免疫逃逸的癌细胞表面抗原。在本研究中，我们使用免疫组织化学、免疫印迹和逆转录聚合酶链反应（RT-PCR）检查了 EBAG9/RCAS1 在人上皮性卵巢癌中的表达。对90例上皮性卵巢癌病例进行了EBAG9和ERα抗体的免疫组织化学检查。检查了 EBAG9 免疫反应性与临床病理学参数之间的相关性。通过 RT-PCR 评估 22 例患者 EBAG9 和 ERα mRNA 的表达。通过免疫印迹法检测 12 种卵巢癌细胞系中 EBAG9 和 ERα 的表达。 90例中有46例（51.1%）在癌细胞表面和细胞质中检测到EBAG9免疫反应性。 EBAG9表达在浆液组织学（P=0.0402）和晚期疾病（P=0.0206）中显着较高。 EBAG9 免疫反应性与总生存率之间未检测到显着关系（P=0.689）。 EBAG9与ER免疫反应性之间存在高度显着相关性(P<0.0001)。 22例中有20例检测到EBAG9 mRNA。在所有 ERα mRNA 呈阳性的病例中，EBAG9 mRNA 也呈阳性。在12个卵巢癌细胞系中的11个中检测到了与EBAG9相对应的免疫反应带，并且与ERα表达一致。总之，EBAG9 的广泛分布及其与晚期疾病的关系表明该蛋白可能在上皮性卵巢癌中发挥重要作用。
Oestrogen receptor-binding fragment associated gene 9, EBAG9, is an oestrogen-responsive gene that was identified in MCF-7 human breast carcinoma cell line. It is identical to RCAS 1, a cancer cell surface antigen possibly involved in immune escape. In the present study, we examined the expression of EBAG9/RCAS1 in human epithelial ovarian cancer using immunohistochemistry, immunoblotting and reverse transcription–polymerase chain reaction (RT–PCR). A total of 90 epithelial ovarian cancer cases were examined immunohistochemically by means of the antibodies for EBAG9 and ERα. The correlation between EBAG9 immunoreactivity and clinicopathological parameters was examined. mRNA expression of EBAG9 and ERα were evaluated by RT–PCR in 22 cases. The expression for EBAG9 and ERα was examined by immunoblotting in 12 ovarian cancer cell lines. EBAG9 immunoreactivity was detected in the surface and cytoplasm of carcinoma cells in 46 out of 90 cases (51.1%). EBAG9 expression was significantly higher in serous histology (P=0.0402) and advanced disease (P=0.0206). No significant relationship was detected between EBAG9 immunoreactivity and overall survival (P=0.689). There was a highly significant correlation between EBAG9 and ER immunoreactivity (P<0.0001). The EBAG9 mRNA was detected in 20 out of 22 cases. In all of the cases that were positive for ERα mRNA, they were also positive for EBAG9 mRNA. Immunoreactive band corresponding to EBAG9 was detected in 11 out of 12 of ovarian cancer cell lines, and was consistent with ERα expression. In conclusion, the wide distribution of EBAG9 and its relation to advanced disease suggest that this protein may play important roles in epithelial ovarian cancer.
登录
查看更多内容
DOI：
10.1111/j.1471-0528.1990.tb16243.x
发表时间：
1990-08-01
期刊：
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY
影响因子：
--
作者：
SEVELDA, P;DENISON, U;SALZER, H
通讯作者：
SALZER, H
影响因子：
5.8
作者：
Sasano, H;Frost, AR;Nagura, H
通讯作者：
Nagura, H
DOI：
10.1111/j.1349-7006.2002.tb01323.x
发表时间：
2002-07
期刊：
Japanese journal of cancer research : Gann
影响因子：
--
作者：
Akahira J;Suzuki T;Ito K;Kaneko C;Darnel AD;Moriya T;Okamura K;Yaegashi N;Sasano H
通讯作者：
Sasano H
影响因子：
4.7
作者：
MASOOD, S;HEITMANN, J;BENRUBI, GI
通讯作者：
BENRUBI, GI
影响因子：
9.7
作者：
Nakakubo, Y;Hida, Y;Katoh, H
通讯作者：
Katoh, H